This suggests that anti-Gal-1 antibody treatment promotes synergistic anti-tumor effects of γδ T cells, therefore offering a more effective adoptive immunotherapy strategy for cervical cancer patients [185]. The gene discussed is LGALS1; the disease is cervical cancer.